Birth weight, breast cancer and the potential mediating hormonal environment

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Bukowski, Radek ^a   Chlebowski, Rowan T ^b   Thune, Inger ^c,d   Furberg, Anne Sofie ^d   Hankins, Gary D V ^a   Malone, Fergal D ^e   D'Alton, Mary E ^f  

^a University of Texas Medical Branch School of Medicine   (United States)

^b LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

^f Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN ANTIBODY; ESTRIOL; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; BIRTH WEIGHT; BODY HEIGHT; BODY WEIGHT; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; COHORT ANALYSIS; CONTROLLED STUDY; ESTRIOL BLOOD LEVEL; FEMALE; HIGH BIRTH WEIGHT; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MENARCHE; PREGNANCY; PROBABILITY; PROPENSITY SCORE; RISK FACTOR;

ALPHA-FETOPROTEINS; BIRTH WEIGHT; BREAST NEOPLASMS; COHORT STUDIES; ESTRIOL; FEMALE; HORMONES; HUMANS; INFANT; MIDDLE AGED; MOTHERS; PREGNANCY; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; RISK FACTORS;

EID: 84863995907     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040199     Document Type: Article

References (47)

1. Joy JE, Penhoet EE, Petitti DB, (2005) Saving Women's Lives: Strategies for Improving Breast Cancer Detection and Diagnosis.
2. Amir E, Freedman OC, Seruga B, Evans DG, (2010) Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst 102: 680-691. djq088 [pii];10.1093/jnci/djq088 [doi].
3. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA, (2001) Validation of the Gail,et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93: 358-366.
4. Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN, (1995) Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 87: 1681-1685.
5. Silva IS, de SB, McCormack V, (2008) Birth size and breast cancer risk: re-analysis of individual participant data from 32 studies. PLoS Med 5: e193. 08-PLME-RA-0764 [pii];10.1371/journal.pmed.0050193 [doi].
6. Cnattingius S, Torrang A, Ekbom A, Granath F, Petersson G, et al. (2005) Pregnancy characteristics and maternal risk of breast cancer. JAMA 294: 2474-2480.
7. Wohlfahrt J, Melbye M, (1999) Maternal risk of breast cancer and birth characteristics of offspring by time since birth. Epidemiology 10: 441-444.
8. Lunde A, Melve KK, Gjessing HK, Skjaerven R, Irgens LM, (2007) Genetic and environmental influences on birth weight, birth length, head circumference, and gestational age by use of population-based parent-offspring data. Am J Epidemiol 165: 734-741. kwk107 [pii];10.1093/aje/kwk107 [doi].
9. Trichopoulos D, (1990) Hypothesis: does breast cancer originate in utero? Lancet 335: 939-940.
10. Westergaard JG, Teisner B, Grudzinskas JG, (1983) Serum PAPP-A in normal pregnancy: relationship to fetal and maternal characteristics. Arch Gynecol 233: 211-215.
11. Vakharia D, Mizejewski GJ, (2000) Human alpha-fetoprotein peptides bind estrogen receptor and estradiol, and suppress breast cancer. Breast Cancer Res Treat 63: 41-52.
12. Lin TM, Halbert SP, Spellacy WN, (1974) Measurement of pregnancy-associated plasma proteins during human gestation. J Clin Invest 54: 576-582. 10.1172/JCI107794 [doi].
13. Yager JD, Davidson NE, (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282. 354/3/270 [pii];10.1056/NEJMra050776 [doi].
14. Melbye M, Wohlfahrt J, Lei U, Norgaard-Pedersen B, Mouridsen HT, et al. (2000) alpha-fetoprotein levels in maternal serum during pregnancy and maternal breast cancer incidence. J Natl Cancer Inst 92: 1001-1005.
15. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, et al. (1999) The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A 96: 3149-3153.
16. Laursen LS, Overgaard MT, Soe R, Boldt HB, Sottrup-Jensen L, et al. (2001) Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lett 504: 36-40.
17. Kuhajda FP, Eggleston JC, (1985) Pregnancy-associated plasma protein A. A clinically significant predictor of early recurrence in stage I breast carcinoma is independent of estrogen receptor status. Am J Pathol 121: 342-348.
18. Yu H, Rohan T, (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472-1489.
19. Yaron Y, Cherry M, Kramer RL, O'Brien JE, Hallak M, et al. (1999) Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 181: 968-974. S0002937899006341 [pii].
20. Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, et al. (2002) Early-pregnancy origins of low birth weight. Nature 417: 916. 10.1038/417916a [doi];417916a [pii].
21. Benn PA, (2002) Advances in prenatal screening for Down syndrome: I. general principles and second trimester testing. Clin Chim Acta 323: 1-16. S0009898102001869 [pii].
22. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH, (2008) First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 31: 493-502. 10.1002/uog.5332 [doi].
23. Bukowski R, Uchida T, Smith GC, Malone FD, Ball RH, et al. (2008) Individualized norms of optimal fetal growth: fetal growth potential. Obstet Gynecol 111: 1065-1076.
24. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP, (1975) The Framingham Offspring Study. Design and preliminary data. Prev Med 4: 518-525.
25. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, et al. (2005) First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 353: 2001-2011.
26. Cepeda MS, Boston R, Farrar JT, Strom BL, (2003) Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 158: 280-287.
27. Royston P, Ambler G, Sauerbrei W, (1999) The use of fractional polynomials to model continuous risk variables in epidemiology. International Journal of Epidemiology 28: 964-974.
28. Sauerbrei W, Royston P, (1999) Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. Journal of the Royal Statistical Society Series A-Statistics in Society 162: 71-94.
29. van BS, Boshuizen HC, Knook DL, (1999) Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 18: 681-694 10.1002/(SICI) 1097-0258(19990330) 18:6<681::AID-SIM71>3.0.CO;2-R [pii].
30. Grambsch PM, Therneau TM, (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515-526.
31. Xue F, Michels KB, (2007) Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. Lancet Oncol 8: 1088-1100. S1470-2045(07)70377-7 [pii];10.1016/S1470-2045(07)70377-7 [doi].
32. Xu X, Dailey AB, Peoples-Sheps M, Talbott EO, Li N, et al. (2009) Birth weight as a risk factor for breast cancer: a meta-analysis of 18 epidemiological studies. J Womens Health (Larchmt) 18: 1169-1178. 10.1089/jwh.2008.1034 [doi].
33. Tehranifar P, Liao Y, Flom JD, Terry MB, (2009) Validity of self-reported birth weight by adult women: sociodemographic influences and implications for life-course studies. Am J Epidemiol 170: 910-917. kwp205 [pii];10.1093/aje/kwp205 [doi].
34. Cresswell JL, Egger P, Fall CH, Osmond C, Fraser RB, et al. (1997) Is the age of menopause determined in-utero? Early Hum Dev 49: 143-148. S0378378297000285 [pii].
35. Kramer MS, (1987) Intrauterine growth and gestational duration determinants. Pediatrics 80: 502-511.
36. Sloboda DM, Hart R, Doherty DA, Pennell CE, Hickey M, (2007) Age at menarche: Influences of prenatal and postnatal growth. J Clin Endocrinol Metab 92: 46-50. jc.2006-1378 [pii];10.1210/jc.2006-1378 [doi].
37. Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulff KH, et al. (2003) Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol 101: 264-272. S0029784402025930 [pii].
38. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, et al. (1994) Transient increase in the risk of breast cancer after giving birth. N Engl J Med 331: 5-9.
39. Collaborative Group on Hormonal Factors in Breast Cancer (2002) Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360: 187-195.
40. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713-1727.
41. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, et al. (2004) Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 101: 1490-1500.
42. Chlebowski R, (2007) Lifestyle change including dietary fat reduction and breast cancer outcome. J Nutr 137: 233S-235S. 137/1/233S [pii].
43. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, et al. (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27: 3235-3258. JCO.2008.20.5179 [pii];10.1200/JCO.2008.20.5179 [doi].
44. Hill M, Parizek A, Kancheva R, Duskova M, Velikova M, et al. (2010) Steroid metabolome in plasma from the umbilical artery, umbilical vein, maternal cubital vein and in amniotic fluid in normal and preterm labor. J Steroid Biochem Mol Biol 121: 594-610. S0960-0760(09)00266-0 [pii];10.1016/j.jsbmb.2009.10.012 [doi].
45. Seppala M, Ruoslahti E, (1972) Alpha-fetoprotein in normal and pregnancy sera. Lancet 1: 375-376.
46. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, et al. (2010) Control of mammary stem cell function by steroid hormone signalling. Nature 465: 798-802. nature09027 [pii];10.1038/nature09027 [doi].
47. Catov JM, Newman AB, Kelsey SF, Roberts JM, Sutton-Tyrrell KC, et al. (2006) Accuracy and reliability of maternal recall of infant birth weight among older women. Ann Epidemiol 16: 429-431. S1047-2797(05)00321-2 [pii];10.1016/j.annepidem.2005.09.004 [doi].